Fiasp (fast-acting insulin aspart) / Novo Nordisk 
Welcome,         Profile    Billing    Logout  
 7 Diseases   10 Trials   10 Trials   866 News 


«123456789»
  • ||||||||||  Tresiba (insulin degludec) / Novo Nordisk, Fiasp (fast-acting insulin aspart) / Novo Nordisk
    New trial, Real-world evidence, Real-world:  CONNECT 1: A Research Study Looking at How the Use of NovoPen (clinicaltrials.gov) -  Oct 5, 2021   
    P=N/A,  N=227, Not yet recruiting, 
  • ||||||||||  Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
    Trial completion, Metastases:  FACT: Fast Advanced Closed-Loop Therapy (clinicaltrials.gov) -  Sep 30, 2021   
    P=N/A,  N=30, Completed, 
    Recruiting --> Completed
  • ||||||||||  Afrezza (recombinant human insulin inhalation) / MannKind
    Enrollment open, Combination therapy:  Afrezza (clinicaltrials.gov) -  Sep 21, 2021   
    P3,  N=264, Recruiting, 
    Recruiting --> Completed Not yet recruiting --> Recruiting
  • ||||||||||  Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
    Trial completion date, Trial primary completion date:  Insulin Fiasp vs. Insulin Novorapid During Pregnancy and Laction in Women With Pre-existing Diabetes (clinicaltrials.gov) -  Sep 16, 2021   
    P3,  N=220, Recruiting, 
    In this case, it was possible to identify aspart insulin and discriminate it from human insulin in a context of attempted murder and subsequent attempted suicide using high-resolution mass spectrometry, which is of paramount importance in forensic medicine. Trial completion date: Oct 2022 --> Apr 2023 | Trial primary completion date: Oct 2021 --> Apr 2022
  • ||||||||||  Fiasp (fast-acting insulin aspart) / Novo Nordisk
    Trial completion date, Trial primary completion date:  AP-MFT-01: Comparison of Day and Night Closed-loop With Faster-acting Insulin Aspart With Insulin Aspart (clinicaltrials.gov) -  Aug 27, 2021   
    P=N/A,  N=22, Recruiting, 
    Trial completion date: Oct 2022 --> Apr 2023 | Trial primary completion date: Oct 2021 --> Apr 2022 Trial completion date: Jun 2021 --> Feb 2022 | Trial primary completion date: Jun 2021 --> Nov 2021
  • ||||||||||  Afrezza (recombinant human insulin inhalation) / MannKind
    Trial completion date, Trial primary completion date, Combination therapy:  Afrezza (clinicaltrials.gov) -  Aug 23, 2021   
    P3,  N=264, Not yet recruiting, 
    Trial completion date: Jun 2021 --> Feb 2022 | Trial primary completion date: Jun 2021 --> Nov 2021 Trial completion date: Apr 2025 --> Apr 2024 | Trial primary completion date: Apr 2024 --> Apr 2023
  • ||||||||||  Fiasp (fast-acting insulin aspart) / Novo Nordisk
    Enrollment change:  Evaluation of Fiasp (clinicaltrials.gov) -  Aug 18, 2021   
    P4,  N=27, Completed, 
    It therefore represents a promising candidate in the pursuit for second generation prandial insulin analogs to improve postprandial glycemic control. N=20 --> 27
  • ||||||||||  Fiasp (fast-acting insulin aspart) / Novo Nordisk
    Journal:  Concentration and Chemical Stability of Commercially Available Insulins: A High-Resolution Mass Spectrometry Study. (Pubmed Central) -  Aug 15, 2021   
    High-resolution mass spectrometry was used to quantify intact monomeric insulin in glass vials and plastic pump cartridges exposed to three different temperatures (4°C, 22°C, 37°C), simulating real-life conditions. In all cases, measured insulin concentration was in accordance with FDA and European Medicines Agency (EMA) requirements without evidence of chemical instability.
  • ||||||||||  Afrezza (recombinant human insulin inhalation) / MannKind
    New P3 trial, Combination therapy:  Afrezza (clinicaltrials.gov) -  Jul 22, 2021   
    P3,  N=264, Not yet recruiting, 
  • ||||||||||  Fiasp (fast-acting insulin aspart) / Novo Nordisk, Apidra (insulin glulisine) / Sanofi, BioChaperone lispro (ultra fast-acting insulin analog) / Adocia
    Clinical, Review, Journal:  The continuing quest for better subcutaneously administered prandial insulins: a review of recent developments and potential clinical implications. (Pubmed Central) -  Jun 26, 2021   
    Insulins, lispro, aspart and glulisine all achieved an earlier onset of action, greater peak effect and shorter duration of action resulting in lower PPG levels and a reduced risk of late postprandial hypoglycaemia...Recent reformulations of aspart and lispro have generated a second generation of more rapid-acting insulin analogue candidates, including fast-acting aspart (faster aspart), ultra-rapid lispro and BioChaperone Lispro...Phase 1 trials for BioChaperone lispro are equally encouraging with Phase 3 trials yet to be initiated. Comparative analysis of the clinical and pharmacological evidence for these new prandial insulin candidates in the treatment of type 1 and type 2 diabetes, is the main focus of this review.
  • ||||||||||  Tresiba (insulin degludec) / Novo Nordisk
    Journal:  Are newer insulin analogues better for people with Type 1 diabetes? (Pubmed Central) -  Jun 8, 2021   
    In the present review we discuss the currently available insulin analogues and the challenges of achieving glucose control using current analogues in those on multiple daily injections, and appraise the evidence base for newer-generation insulin analogues, such as insulin degludec, glargine U300, faster-acting insulin aspart and BioChaperone lispro. We also highlight new insulins in development and unmet needs in people with Type 1 diabetes.
  • ||||||||||  Fiasp (fast-acting insulin aspart) / Novo Nordisk
    Clinical, PK/PD data, Review, Journal:  Fast-Acting Insulin Aspart: A Review of its Pharmacokinetic and Pharmacodynamic Properties and the Clinical Consequences. (Pubmed Central) -  May 26, 2021   
    Indeed, change from baseline in 1-h postprandial glucose increment is in favour of faster aspart versus IAsp when used as basal-bolus or CSII treatment in phase III trials in subjects with T1D or T2D. This review summarises the currently published results from clinical pharmacology trials with faster aspart and discusses the potential clinical benefits of faster aspart compared with previous rapid-acting insulin products.
  • ||||||||||  Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
    Phase classification, Metastases:  FACT: Fast Advanced Closed-Loop Therapy (clinicaltrials.gov) -  May 13, 2021   
    P=N/A,  N=33, Recruiting, 
    The simulation studies indicate that using Fiasp® in place of NovoLog® with the MiniMed 670G system will significantly improve the time spent in the healthy, euglycemic range and reduce exposure to hyperglycemia and hypoglycemia in most patients. Phase classification: P4 --> P=N/A
  • ||||||||||  Fiasp (fast-acting insulin aspart) / Novo Nordisk
    Trial completion date, Trial primary completion date:  Comparison of FiAsp and Aspart During Postprandial Exercise in Adults With Type 1 Diabetes (clinicaltrials.gov) -  May 6, 2021   
    P4,  N=40, Recruiting, 
    Phase classification: P4 --> P=N/A Trial completion date: Feb 2021 --> May 2022 | Trial primary completion date: Feb 2021 --> Feb 2022
  • ||||||||||  Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
    New P4 trial, Metastases:  FACT: Fast Advanced Closed-Loop Therapy (clinicaltrials.gov) -  Apr 20, 2021   
    P4,  N=33, Recruiting, 
  • ||||||||||  Symlin (pramlintide) / AstraZeneca, Fiasp (fast-acting insulin aspart) / Novo Nordisk
    Trial completion:  Pramlintide and Fiasp Closed-Loop With a Simple Meal Announcement (clinicaltrials.gov) -  Apr 1, 2021   
    P=N/A,  N=8, Completed, 
    Not yet recruiting --> Recruiting Recruiting --> Completed
  • ||||||||||  Fiasp (fast-acting insulin aspart) / Novo Nordisk
    [VIRTUAL] GAD-associated encephalitis in a 15-year-old boy with type I diabetes mellitus: a case report (Zoom Channel 4) -  Mar 21, 2021 - Abstract #DDG2021DDG_87;    
    The present case report supports the growing literature on autoimmune neurological diseases associated with high GAD antibody titers (1-3). Therefore, in the case of neurological symptoms in children and adolescents with type I DM, this association should be considered and, if necessary, appropriate immunodiagnostics performed.
  • ||||||||||  Fiasp (fast-acting insulin aspart) / Novo Nordisk
    Trial completion, Real-world evidence, Real-world:  Effect of Fiasp (clinicaltrials.gov) -  Feb 21, 2021   
    P=N/A,  N=244, Completed, 
    Therefore, in the case of neurological symptoms in children and adolescents with type I DM, this association should be considered and, if necessary, appropriate immunodiagnostics performed. Enrolling by invitation --> Completed
  • ||||||||||  Fiasp (fast-acting insulin aspart) / Novo Nordisk
    Enrollment open:  An Indian Post Marketing Study of Mealtime Insulin, Fiasp (clinicaltrials.gov) -  Feb 17, 2021   
    P=N/A,  N=300, Enrolling by invitation, 
    In combination with insulin degludec, faster aspart provided effective overall glycemic control, superior PPG control, and a lower rate of severe or BG-confirmed hypoglycemia versus IAsp in adults with type 2 diabetes not optimally controlled with a basal-bolus regimen. Not yet recruiting --> Enrolling by invitation
  • ||||||||||  Fiasp (fast-acting insulin aspart) / Novo Nordisk
    Enrollment open:  Fast-Acting Insulin Aspart and Insulin Pump Settings (clinicaltrials.gov) -  Feb 15, 2021   
    P4,  N=40, Recruiting, 
    Not yet recruiting --> Enrolling by invitation Not yet recruiting --> Recruiting